We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Patient Access to MRI Scans Expanded with CE Marking Approval for Pacemaker Leads

By HospiMedica International staff writers
Posted on 08 Oct 2014
New pacemaker leads have received CE marking approval, allowing existing and future patients with the devices access to magnetic resonance imaging (MRI) scans in Europe. More...


St. Jude Medical, Inc. (St. Paul, Minnesota, USA), a global medical device company, has announced CE marking approval of updated labeling for its Tendril STS and IsoFlex Optim. The leads are used with the Accent MRI pacemaker, an advanced pacing platform that provides the added benefit of MRI scanning capability.

“St. Jude Medical is committed to providing MRI-compatible pacing solutions to patients and physicians around the world,” said Eric S. Fain, MD, group president of St. Jude Medical. “We believe many patients can benefit from pacing therapies with MRI scanning capabilities when they have additional health concerns. We are dedicated to the development of existing and future heart rhythm technologies that are compatible with this important diagnostic tool.”

Yearly, approximately one million pacemakers are implanted worldwide. The Tendril STS and IsoFlex Optim pacing leads are built on the Tendril and IsoFlex lead platforms, and include the company’s exclusive Optim insulation material. Optim insulation is a hybrid insulation material that blends the biostability and flexibility of high-performance silicone rubber with the strength, tear resistance and abrasion resistance of polyurethane. This combination is designed to provide increased durability, and to improve flexibility, handling characteristics and control during implant procedures. The updated labeling further demonstrates the safety of the Tendril STS and IsoFlex Optim pacing leads, which were originally designed to be used in an MRI setting. In actively monitored registries, the Tendril STS and IsoFlex Optim pacing leads have demonstrated effectiveness with over 99% survivability in patients.

St. Jude Medical reported, in addition to this approval, that it plans to seek updated labeling for many existing products to allow patients the ability to safely undergo MRI scans. St. Jude Medical plans to submit testing data in key markets worldwide such as Europe, Japan, Australia, and the United States for MRI conditional labeling on several additional existing products including the Fortify Assura implantable cardioverter defibrillator (ICD), Ellipse ICD, Quadra Assura cardiac resynchronization therapy defibrillator (CRT-D), Durata and Optisure defibrillation leads.

Related Links:

St. Jude Medical



Gold Member
12-Channel ECG
CM1200B
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
POC Respiratory/Sore Throat Test
BIOFIRE SPOTFIRE (R/ST) Panel
Surgical Dressing
ALLEVYN Ag+ SURGICAL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Graphical Abstract (Aoibhin M. Sheedy et al., A replenishable peritoneal implant for localized delivery and peritoneal fluid sampling in ovarian cancer, Device (2026). DOI: 10.1016/j.device.2026.101050)

New Implant Provides Sustained Localized Therapy for Ovarian Cancer

Ovarian cancer is often diagnosed at advanced stages because symptoms such as bloating, pain, and pelvic pressure are nonspecific. Standard care relies on surgery and systemic therapy, yet tools for targeted... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.